Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
months, with Wall Street anticipating a further uptick of nearly 60%, as of the close of business on January 12. However, on January 6, Wolfe Research downgraded the stock to Peer Perform from Outperform, and according to a report on TipRanks, the firm also removed its $92 price target for the company's shares. In a research note to investors, Wolfe Research described the stock as ‘a poor investment in 2026', citing a lack of catalysts that could drive an upside and valuation concerns about the stock among investors. However, the firm's analyst still considers Kymera Therapeutics, Inc. (NASDAQ:KYMR) a good investment over the long term. On the same day, BTIG reiterated its Buy rating on the stock with a share price target of $138. Earlier on January 5, Citigroup also kept its Buy rating and maintained an earlier price target of $110 on its shares. In December, the company announced that it had received Fast Track designation from the FDA for its KT-621 oral STAT6 degrader to t
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $138.00 price target on the stock.MarketBeat
- Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology ProgramsGlobeNewswire
- Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- Is Kymera Therapeutics (KYMR) Balancing Pipeline Ambition and Execution Risk After New KT-621 Milestone? [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13GlobeNewswire
KYMR
Earnings
- 11/4/25 - Miss
KYMR
Sec Filings
- 1/13/26 - Form 8-K
- 1/8/26 - Form SCHEDULE
- 1/6/26 - Form 4
- KYMR's page on the SEC website